Copenhagen, Denmark, December 20, 2016
Vipergen ApS announced today the signing of a multi-target drug discovery agreement with Merck. Under the terms of the agreement, Vipergen’s small molecule discovery engine, a proprietary high fidelity DNA-encoded library technology platform, will be applied across therapeutic projects to identify novel hits for selected targets from Merck. Merckobtains exclusive options to selected hits/leads and hit/lead series. The therapeutic areas of the targets were not disclosed, nor were the financial details of theagreement.
“We are very proud to be selected by Merck, a global industry leader in drug discovery and development.” said Nils Hansen, Chief Executive Officer of Vipergen. “Vipergen has designed and implemented its discovery engine to deliver high quality hits and leads for very challenging but important protein targets as Merckis tackling to address unmet medical needs. We look forward to working with Merck.”
About Vipergen ApS
Vipergen is dedicated to small molecule drug discovery using DNA-encoded library platforms.Vipergen leverages its innovative and proprietary drug discovery platforms in partnerships with leading pharmaceutical and biotech companies. Vipergen ́s two 2ndgenerationtechnology platforms -The YoctoReactor®for synthesizing DNA-encoded chemical libraries and Binder Trap Enrichment®for screening of such libraries -are designed to deliver high fidelity drug discovery. For further details about Vipergen and the YoctoReactor®/ Binder Trap Enrichment®drug discovery technology platforms please visit www.vipergen.com or contact:
Vipergen ApS
Dr. Nils Hansen,
Chief Executive Officer
Phone: +45 2523 6680
[email protected]